

Sample Language for Tie Tag Label

Psoralen Treated Platelets:

Leukocytes (T-cells) & cytomegalovirus (CMV) are inactivated by treatment with the INTERCEPT® Blood System (psoralen treatment). Both the FDA and the AABB (Standard 5.19.3.1 for irradiation of blood products) considers the FDA approved psoralen treated method of pathogen reduction equivalent to irradiation.

If the decision is made to include a tie tag on INTERCEPT Blood System (psoralen treated) platelet products in place of a RadSure label that is used on conventional platelets, a transfusion policy should be created to describe this step in your platelet distribution process.

Language that you may consider to use on your tie tag include:

- Pathogen reduction (e.g. INTERCEPT treatment) of platelets is an FDA approved alternative to gamma irradiation of platelets.¹
- INTERCEPT treatment provides cytomegalovirus (CMV) inactivation at levels meeting the AABB Standard 5.19.2 policy requiring methods to reduce CMV transmission risk.²
- Pathogen reduction by psoralen treatment is FDA approved as an alternative to gamma irradiation and also meets AABB CMV mitigation standards.^{1,2}

References

- 1. INTERCEPT Blood System for Platelets [Package Insert]. Concord, CA: Cerus Corporation; July 17, 2018.
- 2. AABB. Standards for Blood Banks and Transfusion Services 31st Edition. (AABB, Bethesda, MD, 2018).



GLOBAL HEADQUARTERS | 1220 Concord Avenue | Concord, CA US 94520 | 855.835.3523 www.cerus.com | www.intercept-usa.com | hcp.intercept-usa.com Rx only. See package insert for full prescribing information.